Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;14(5):857-872.
doi: 10.1007/s12265-021-10108-w. Epub 2021 Feb 25.

N6-Adenosine Methylation (m6A) RNA Modification: an Emerging Role in Cardiovascular Diseases

Ye-Shi Chen #  1   2 , Xin-Ping Ouyang #  3   4 , Xiao-Hua Yu #  5 , Petr Novák  2 , Le Zhou  2 , Ping-Ping He  6   7 , Kai Yin  8
Affiliations
Review

N6-Adenosine Methylation (m6A) RNA Modification: an Emerging Role in Cardiovascular Diseases

Ye-Shi Chen et al. J Cardiovasc Transl Res. 2021 Oct.

Abstract

N6-methyladenosine (m6A) is the most abundant and prevalent epigenetic modification of mRNA in mammals. This dynamic modification is regulated by m6A methyltransferases and demethylases, which control the fate of target mRNAs through influencing splicing, translation and decay. Recent studies suggest that m6A modification plays an important role in the progress of cardiac remodeling and cardiomyocyte contractile function. However, the exact roles of m6A in cardiovascular diseases (CVDs) have not been fully explained. In this review, we summarize the current roles of the m6A methylation in the progress of CVDs, such as cardiac remodeling, heart failure, atherosclerosis (AS), and congenital heart disease. Furthermore, we seek to explore the potential risk mechanisms of m6A in CVDs, including obesity, inflammation, adipogenesis, insulin resistance (IR), hypertension, and type 2 diabetes mellitus (T2DM), which may provide novel therapeutic targets for the treatment of CVDs.

Keywords: Cardiovascular diseases; Demethylase; Epitranscriptomics; Methyltransferase; N6-methyladenosine (m6A).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kim, T. K., Gore, S. D., & Zeidan, A. M. (2015). Epigenetic therapy in acute myeloid leukemia: current and future directions. Seminars in Hematology, 52, 172–183. - PubMed - PMC
    1. Wu, X., Sang, L., & Gong, Y. (2018). N6-methyladenine RNA modification and cancers. American Journal of Cancer Research, 8, 1957–1966. - PubMed - PMC
    1. Roundtree, I. A., Evans, M. E., Pan, T., & He, C. (2017). Dynamic RNA modifications in gene expression regulation. Cell, 169, 1187–1200. - PubMed - PMC
    1. Adams, J. M., & Cory, S. (1975). Modified nucleosides and bizarre 5’-termini in mouse myeloma mRNA. Nature, 255, 28–33. - PubMed
    1. Desrosiers, R., Friderici, K., & Rottman, F. (1974). Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proceedings of the National Academy of Sciences of the United States of America, 71, 3971–3975. - PubMed - PMC

Publication types

LinkOut - more resources